{"id":117713,"name":"PHRMA INC.","slug":"phrma-inc","state":"DC","country":"United States of America","description":"Represents leading research-based pharmaceutical and biotechnology companies in the US","totalSpending":2100000,"filings":29,"yearlySpending":[{"year":2018,"income":300000},{"year":2019,"income":275000},{"year":2020,"income":300000},{"year":2021,"income":300000},{"year":2022,"income":300000},{"year":2023,"income":300000},{"year":2024,"income":300000},{"year":2025,"income":25000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"BUD","display":"Budget/Appropriations"},{"code":"MMM","display":"Medicare/Medicaid"},{"code":"TRD","display":"Trade (domestic/foreign)"}],"firms":["THE DUBERSTEIN GROUP INC."],"lobbyists":["BRIAN GRIFFIN","ANNE BRADBURY","DANIEL MEYER","DAVID SCHIAPPA","ANNE WALL","KATHERINE KEATING","BENJAMIN HOWARD","ELIZABETH KELLEY"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","White House Office","Treasury, Dept of","Health & Human Services, Dept of (HHS)","Labor, Dept of (DOL)"],"sampleDescriptions":["Drug Pricing","Pay-Fors.\n\nMedicare Part D:\nHR 1625 (Royce) - Consolidated Appropriations Act, 2018\nHR 1892 (Larson) - Bipartisan Budget Act of 2018","Medicare Part D:\nHR 1625 (Royce) - Consolidated Appropriations Act, 2018\nHR 1892 (Larson) - Bipartisan Budget Act of 2018\n\nPay-fors.","Drug Pricing\n\nCREATES Act","Medicare Part D:\nHR 1625 (Royce) - Consolidated Appropriations Act, 2018\nHR 1892 (Larson) - Bipartisan Budget Act of 2018\n\nDrug Pricing\n\nPay-fors."]}